Radiotherapy cost-calculation and its impact on capacity planning.

abstract：:Treatment switching has become an important issue in the development and approval of new drugs, particularly in oncology. Randomized controlled trials (RCTs) represent the gold standard for evaluating the effectiveness of interventions, but often patients randomized to the control group are permitted to switch onto th...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Latimer NR

更新日期：2015-01-01 00:00:00

abstract：:The 10th consecutive World Health Economics conference was organized jointly by International Health Economics Association and European Conference on Health Economics Association and took place at The Trinity College, Dublin, Ireland in July 2014. It has attracted broad participation from the global professional commu...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Jakovljevic MB,Getzen TE,Torbica A,Anegawa T

更新日期：2014-12-01 00:00:00

abstract：BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospit...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap M

更新日期：2018-04-01 00:00:00

abstract：:In 2001, the US National Cancer Institute created the Cancer Outcomes Measurement Working Group (COMWG) to assess the state-of-the-science of outcomes assessment in cancer and to make recommendations for moving the field forward. The COMWG focused on methods for assessing patient-reported outcomes (health-related QoL,...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Snyder C,Gotay CC,Lipscomb J

更新日期：2006-08-01 00:00:00

abstract：:Skin diseases are among the most common health problems worldwide and are associated with a considerable burden. The burden of skin disease is a multidimensional concept that encompasses psychological, social and financial consequences of the skin disease on the patients, their families and on society. Chronic and inc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Basra MK,Shahrukh M

更新日期：2009-06-01 00:00:00

abstract：INTRODUCTION:During the past few years, medical-economic evaluation of lung cancers (LCs) has become unavoidable. Total management costs have been rising constantly, with values almost doubling every 10 years. The financial impact will be even greater with the new molecules now marketed. The methodology for these studi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Vergnenègre A,Chouaïd C

更新日期：2018-10-01 00:00:00

abstract：:The 15th International Symposium for Health Information Management Research (ISHIMR) was organized jointly by University Hospital Zurich (Switzerland), the University of St Gallen (St Gallen, Switzerland) and the University of Sheffield (Sheffield, UK). Participants included researchers, healthcare professionals, heal...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bath PA,Sen BA,Raptis DA,Mettler T

更新日期：2012-02-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Márquez-Cruz M,Díaz-Martínez JP,Soto-Molina H,De Saráchaga AJ,Cervantes-Arriaga A,Llorens-Arenas R,Rodríguez-Violante M

更新日期：2016-01-01 00:00:00

abstract：:In health and disability arenas, it is increasingly being recognized that removing or modifying environmental factors can have a greater influence over outcomes than many individually focused interventions. In 2001, the World Health Organization endorsed a major revision of its framework for assessing and classifying ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuipers P,Foster MM,Bellamy N

更新日期：2003-04-01 00:00:00

abstract：:This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2014-10-01 00:00:00

abstract：:Given growing interest in multicriteria decision making and multiple cost-effectiveness thresholds' approach, it was decided to investigate its usefulness in Poland. The pricing and reimbursement (P&R) regulations were reviewed and a cross-sectional survey was conducted amongst nurses. The study investigated whether P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kolasa K

更新日期：2014-10-01 00:00:00

abstract：BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Grewal S,Ramsey S,Balu S,Carlson JJ

更新日期：2018-08-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurological disease affecting older adults. Consequently, this disease should be a focus among payers, with increasing utilization of newer premium-priced patent-protected add-on therapies to stabilize or even improve motor function over time. However, expenditure ca...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brkicic LS,Godman B,Voncina L,Sovic S,Relja M

更新日期：2012-06-01 00:00:00

abstract：:This article systematically appraises the findings and conclusions derived from six recent studies of the economic impact and relative value of using percutaneous ventricular assist devices to render short-term hemodynamic support to high-risk patients with particular attention to the settings of cardiogenic shock and...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Maini B,Scotti DJ,Gregory D

更新日期：2014-06-01 00:00:00

abstract：BACKGROUND:Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers and facilitator...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feig C,Cheung KL,Hiligsmann M,Evers SMAA,Simon J,Mayer S

更新日期：2018-04-01 00:00:00

abstract：:This article reports on the 'Assessing Cost-Effectiveness' (ACE) initiative in priority setting from Australia. It commences with why priority setting is topical and notes that a wide variety of approaches are available. In assessing these various approaches, it is argued that a useful first step is to consider what c...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Carter R,Vos T,Moodie M,Haby M,Magnus A,Mihalopoulos C

更新日期：2008-12-01 00:00:00

abstract：AIMS:To estimate the direct and indirect costs associated with disability due to multiple sclerosis (MS) in Poland. METHODS:Recently a cost-of-illness study was conducted in the Czech Republic, involving 909 patients with different levels of disability (the COMS study). Data on resource use from this trial was extrapo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Szmurło D,Fundament T,Ziobro M,Kruntorádová K,Doležal T,Głogowski C

更新日期：2014-06-01 00:00:00

abstract：:Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to re...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Embleton ND,Dharmaraj ST,Deshpande S

更新日期：2007-10-01 00:00:00

abstract：:Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hegde UP,Chakraborty N,Mukherji B,Grant Kels JM

更新日期：2011-04-01 00:00:00

abstract：:Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sankaranarayanan J,Reardon T,Olsen KM

更新日期：2014-10-01 00:00:00

abstract：:Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gladman DD,Brown RE

更新日期：2008-04-01 00:00:00

abstract：:This review examines the national trends in out-of-pocket and high economic burden of prescription drug expenditures by elderly people aged 65 years and older. From 1992 to 2000, prescription out-of-pocket drug expenditures increased at an annual rate of 7%. During this period the proportion of elderly without prescri...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sambamoorthi U,Akincigil A,Wei W,Crystal S

更新日期：2005-06-01 00:00:00

abstract：:Rheumatoid arthritis is a chronic inflammatory musculoskeletal disease with a prevalence rate of 1-3% in Western countries. In addition to limited physical function, rheumatoid arthritis patients also suffer from psychologic comorbidities. Depression in rheumatoid arthritis patients has been linked to disease outcomes...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Nichol MB,Zhang L

更新日期：2005-10-01 00:00:00

abstract：:Asthma is an inflammatory disorder with increasing prevalence and significant morbidity worldwide. Inhaled steroids improve asthma symptoms, reduce exacerbations number and severity, and the need for oral steroids. Due to their potent anti-inflammatory effect, inhaled steroids represent the most effective maintenance ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoniu SA

更新日期：2003-06-01 00:00:00

abstract：INTRODUCTION:Pharmacogenomic testing has the potential to greatly benefit patients by enabling personalization of medication management, ensuring better efficacy and decreasing the risk of side effects. However, to fully realize the potential of pharmacogenomic testing, there are several important issues that must be a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Moyer AM,Caraballo PJ

更新日期：2017-12-01 00:00:00

abstract：:The main analytic problems for assessing the equality of means of healthcare costs are the skewed and heteroscedastic nature of the distribution of healthcare costs and the occurrence of persons with zero cost values. Without taking these special features into consideration, any statistical method may lead to the wron...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Zhou XH,Ramsey S

更新日期：2003-10-01 00:00:00

abstract：:Recently, the person tradeoff method has received much attention because it directs one to value health improvements of those other than one's self. As a result, several researchers have suggested that the person tradeoff measures preferences in pharmaceutical and health economic analysis more accurately than the stan...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Doctor JN,Miyamoto JM

更新日期：2005-12-01 00:00:00

abstract：:The prevalence of multiple chronic conditions (MCC) is increasing among individuals of all ages. MCC are associated with poor health outcomes. The presence of MCC has profound healthcare utilization and cost implications for public and private insurance payers, individuals, and families. Investigators have used a vari...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sambamoorthi U,Tan X,Deb A

更新日期：2015-01-01 00:00:00

abstract：:It is well accepted that psoriasis has a profound impact on the life of the patient. Moderate-to-severe psoriasis frequently requires phototherapy or aggressive systemic treatment; unfortunately these treatments have major limitations. New biologic treatments are now available that offer distinct safety advantages and...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Feldman SR,Pearce DJ

更新日期：2004-10-01 00:00:00

abstract：INTRODUCTION:In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kwon SH,Park SK,Byun JH,Lee EK

更新日期：2017-08-01 00:00:00